Altered cell-matrix contact: a prerequisite for breast cancer metastasis? by Gui, G. P. et al.
British Journal ofCancer(1997) 75(5), 623-633
© 1997 Cancer Research Campaign
Altered cell-matrix contact: a prerequisite for breast
cancer metastasis?
GPH Gui1, JR Puddefoot2, GP Vinson2, CA Wells3 and R Carpenter1
'Department of Surgery, The Royal Hospitals Trust Breast Unit, St Bartholomew's Hospital, 2nd Floor King George V Block, West Smithfield,
London EClA 7BE; 2Department of Biochemistry, Queen Mary and Wesffield College, Mile End Road, London El 4NS; 3Department of Pathology,
The Royal Hospitals Trust Breast Unit, St Bartholomew's Hospital, 2nd Floor King George V Block, West Smithfield, London ECIA 7BE, UK
Summary The integrins are receptors that regulate interaction between epithelial cells and the extracellular matrix. Previous studies have
shown that a reduction in the expression of the a2p1, a3p3l, a6p1, av31 and avP5 integrins in primary breast cancer is associated with
positive nodal status. In order to assess the functional significance of altered integrin expression, primary breast cancer cells were derived
from individual patients with known tumour characteristics using immunomagnetic separation. Purified human fibronectin, vitronectin, laminin
and type IV collagen were used to represent the principal extracellular matrix proteins in an in vitro adhesion assay. Primary breast cancer
cells from lymph node-positive patients were significantly less adhesive to each of the matrix proteins studied (P<0.001, Mann-Whitney U-
test). Matrix adhesion of primary breast cancer cells from node-negative patients was inhibited by appropriate integrin monoclonal antibodies
(P<0.001, paired Wilcoxon test). Adhesion to fibronectin, vitronectin and laminin, but not type IV collagen, was influenced by the inhibitor
arginine-glycine-aspartate, suggesting that breast cancer cell recognition of collagen IV is mediated through alternative epitopes. Weak
matrix adhesion correlated with loss of integrin expression in tissue sections from corresponding patients assessed using immuno-
histochemistry. This study demonstrates a link between altered integrin expression and function in primary breast cancers predisposed to
metastasize.
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Focal contact with the extracellular matrix is a fundamental mech-
anism by which cells initiate intracytoplasmic signalling in order
to regulate attachment, migration, differentiation and growth
(Burridge et al, 1988). The anatomical basis forcell-matrix recog-
nition is a group of transmembrane receptors called the cell adhe-
sion molecules that include the integrins, cadherins, selectins and
the immunoglobulin superfamily (Albelda and Buck, 1990). The
integrins are the principal receptors that facilitate cellular interac-
tion to the extracellular matrix through binding to specific sites in
fibronectin, vitronectin, laminin and collagen (Hynes, 1992). The
integrins consist ofvarying a and , subunits that associate to form
heterodimers. Fourteen a and eight subunits have been identi-
fied that associate to form 20 known integrins, each categorized
into subfamilies based upon the common ,B subunit (Hynes, 1987).
Each integrin heterodimer bears a receptor site towards the amino
terminal in the extracellular domain. The carboxyl end is
contained within the cell and provides a link to the cytoskeleton
via the cytosolic proteins talin, vinculin and actin (Horwitz et al,
1986; Otey et al, 1993). Intracellular signalling following ligation
of integrin receptors is known to involve phosphorylation path-
ways (Kornberg et al, 1992). Current attention has focused on a
novel 125 kDa protein called focal adhesion kinase ppl25fak
(Burridge et al, 1992). Integrins signal into the cell, as conven-
tional receptors, but, in addition, are also able to transmit informa-
tion from within the cell to the matrix as well as to other cells via a
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mechanism termed inside-out signalling (Hynes, 1992).The versa-
tile nature of integrin function makes these receptors a critical
point ofstudy when cell-matrix interactions are considered.
Several unique peptide epitopes have been identified as recogni-
tion sequencesforintegrinreceptors.Thebestcharacterized ofthese
is the tripeptide arginine-glycine-aspartate, abbreviated to RGD
(Humphries, 1990). While RGD may be used as a general inhibitor
of integrin function, specific receptor-ligand interaction may be
investigated using monoclonal antibodies raised againstthe compo-
nent subunits of each heterodimer (Yamada et al, 1990). Altered
cell-matrix interaction is an essential prerequisite step in the
metastatic cascade (Hart and Saini, 1992). Reduced integrin expres-
sion has been described in primary breast cancer cells compared
with their benign counterparts (Zutter et al, 1990; Pignatelli et al,
1991; Koukoulis et al, 1991), and altered function may be related to
thepresenceofaxillarynodalmetastasis (Guietal, 1995a).Wehave
previously described a methodofisolating live human breastcancer
cells from individual patients foruse in shortterm in vitro studies of
adhesion to laminin (Gui et al, 1995b). The use of these patient-
derived cells is of obvious benefit compared with propagated cell
lines in that it allows the study of breast cancers in women with
known pathological characteristics andnodal status. The aimofthis
study was to evaluate cell-matrix adhesion in tumour progression.
Fibronectin and vitronectin were used to assess cell adhesion to the
interstitial matrix, while laminin and type IV collagen were used to
represent the basement membrane. Our hypothesis was that human
primary breast cancer cells that had lost integrin expression were
less adhesive and therefore predisposed to metastasize.
Part ofthis work was presented to the Surgical Research Society in Glasgow on
6 July 1994
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MATERIALS AND METHODS
Patients
Tumour samples were obtained from 41 patients with stage I or II
invasive ductal breast cancer treated primarily by surgery at the
Royal Hospitals Trust Breast Unit at St Bartholomew's. All
patients were offered either a segmental or simple mastectomy
with formal axillary dissection to evaluate nodal status. Routine
staging investigations included a chest radiograph, serum liver
enzyme biochemistry and corrected calcium. To exclude distant
metastasis, liver ultrasonography and 99technetium radioisotope
bone scans were performed when clinically indicated.
Inhibitory peptides and integrin monoclonal antibodies
The active inhibitor of integrin function, RGD, and the inactive
tripeptide, arginine-glycine-glutamic acid (RGE), were obtained
from Sigma Chemical Company, Poole, Dorset, UK. Integrin
monoclonal antibodies against the a2 (P1E6), a3 (PiB5), 01
(MAbl3), ,P3 (7F12), P5 (PlF6) (all from Becton-Dickinson,
Oxford, UK) and a6 subunits (CLB-701) (Chemicon, London,
UK) were used to evaluate integrin expression by immunohisto-
chemistry, and cell-matrix adhesive function in the in vitro assay.
Immunomagnetic separation
The method of isolating breast cancer cells using immunomag-
netic separation was modified from that of Motoyasu et al (1989)
for bile duct epithelium and has been described in detail in our
previous work (Gui et al, 1995b). Briefly, fresh sterile breast
cancer samples were transported in Dulbecco's modified Eagle
medium (DMEM; Sigma) containing 4.5 g 1-1 glucose, 10% fetal
bovine serum,4 mmol 1-' L-glutamine, 2 mmol 1-1 sodiumpyruvate,
10 ml 1-1 non-essential amino acids, 100 U ml-1 penicillin, 100 jig
ml- streptomycin, 5 jg ml-l fungizone and 50 U ml-' polymyxin B
(ICN Biomedicals, Thame, UK). Each breast cancer segment was
disaggregated in collagenase (Gibco BRL, Paisley, UK) at 5 units
mg-' tissue in DMEM containing 5% fetal bovine serum, 5 jg ml-'
bovine insulin, 100 U ml-' penicillin, 100 jg ml-1 streptomycin,
5 jg mlF1 fungizone and 50 U ml-' polymyxin B on a vertical
rotator at 37°C overnight. Cells were recovered by centrifugation
at 900 r.p.m. and viability assessed using trypan blue exclusion
(Sigma). Dynabeads M-450 (Dynal UK, Wirral, Merseyside, UK),
precoated with rat anti-mouse IgG2a, were incubated with anti-
body toepithelial membrane antigen (EMA) (Taylor-Papadimitrou
et al, 1981) (Dako, High Wycombe, Bucks, UK) to target breast
cancer cells in the disaggregated suspension. The assay was
performed at 4°C to prevent non-specific adhesion. The beads
were detached by a combination of immunological methods
(Rasmussen et al, 1992) using Detach-a-Bead (Dynal UK) and
mechanical procedures (Gui et al, 1995b).
Breast cancer cell clusters separated by the Magnetic Particle
Container (Dynal UK) were dispersed into individual cells using
0.2% trypsin (ICN Biomedicals). The epithelial origin of the puri-
fied cell suspension was established by positive staining to EMA
and the anti-human cytokeratin, CAM5.2, in conjunction with
negative staining to the common leucocyte antigen CD45 and
fibroblast markers (all fromDako UK). The malignant nature ofthe
isolated cells was confirmed morphologically. Tissue samples were
discarded, if adjacent cryostat sections contained recognizable
Table 1 Tumour characteristics of patients studied
Node-negative Node-positive
(n = 20) (n = 21)
Mean patient age (range) years 56.8(33-84) 57.2(37-85)
Mean tumour size (range) cm 2.4 (1.0-4.0) 3.5 (1.0-9.0)
Grade (%)
n= 4(20) n= 1(5)
11 n= 7(35) n= 8(38)
III n= 9(45) n= 12(57)
Vascular invasion present (%) n = 1(5) n = 14(67)
Mean number of involved nodes (range) 0 5.2(1-25)
Mean number of nodes obtained (range) 13.3(5-26) 12.4(3-26)
benign breast cells. The reliability of immunomagnetic separation
as amethod ofproducing breastcancercell isolates and dataon cell
survival times have been established previously (Gui et al, 1995b).
Histology and immunochemistry
Routine tumour and lymph node pathology was assessed on 3-jm
paraffin-embedded sections stained with haematoxylin and eosin.
All negative lymph nodes were, in addition, stained with CAM5.2
(Becton-Dickinson) to exclude occult metastasis. Immuno-
histochemistry was performed on 5-jim primary breast cancer
cryostat sections using the avidin-biotin-peroxidase complex
technique (Hsu et al, 1981). Appropriate biotinylated antibodies
and streptavidin peroxidase-conjugated antibodies (Dako UK)
were used as secondary and tertiary layers respectively. All slides
stained using immunohistochemistry were double read by two
independent observers and scored as negative (-), weak (+),
moderate (++) or strong (+++).Equivocal tumourcell staining was
considered to be negative. Preservation of the integrin receptors
after enzymatic disaggregation was confirmed by immunocyto-
chemistry in cell smears snap frozen in liquid nitrogen.
In vitro adhesion assay
In preliminary studies, flat-bottomed 96-well plates were coated
with graded concentrations (0.1-1000 jig ml-) ofeach ofpurified
human fibronectin, vitronectin, laminin (Collaborative Biomedical
Products, Oxford, UK) and type IV collagen (Sigma). These
experiments demonstrated that maximal cell adhesion to each
protein was achieved after a 4-h incubation period at matrix
concentrations of 100 jg ml-1, and these parameters were selected
as standard conditions for subsequent studies. Survival studies of
primary breast cancer cell isolates based on trypan blue exclusion
had shown viability in wells coated with these matrix proteins of
up to 12 h after completion ofimmunomagnetic separation.
In the experiments described in this paper, all wells were rehy-
drated with 100 jig ml-' bovine serum albumin before use. The
breast cancer cell suspension was diluted to contain 10 000 cells
per ml in serum-free DMEM, and aliquots of50jl containing 500
cells were added to each well. Graded amounts of RGD, RGE
(0-300jig ml-1) orintegrin monoclonal antibodies (0-150jig ml-')
were used to inhibit cell-matrix adhesion. All experiments were
conducted in triplicate at 37°C in a humidified carbon dioxide
incubator. After incubation for 4 h, wells were washed and
numbers of adherent cells estimated using spectrophotometric
absorbance following uptake of 3-[4,5]dimethylthiazol-2-yl-2,5
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Figure 1 Differences in primary breast cancer cell-matrix adhesion with nodal status. Cell adhesion was assessed to matrices of purified human (A) fibronectin,
(B) vitronectin, (C) laminin and (D) type IV collagen, at concentrations of 100,g ml-'. Each box and whisker plot is represented by the median value (within the
box) bounded by the 25th and 75th centiles (short edges of the box), while the bars show the 10th and 90th centiles. Individual observations lying outside this
range are represented by circles. This convention is maintained in Figures 3 and 5. LN-, lymph node negative; LN+, lymph node positive; P, P-values,
Mann-Whitney U-test
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Figure 2 Inhibition of primary breast cancer cell adhesion by varying RGD concentrations to (A) fibronectin, (B) vitronectin, (C) laminin and (D) type IV
collagen, each matrix at concentrations of 100 ,ug ml-'. Primary breast cancer cells from integrin-positive patients were applied to triplicate wells. The bars
represent the standard error of the mean
diphenyltetrazolium bromide (MTT) by live cells (Carmichael
et al, 1987) (Sigma).
Statistical analysis
Cell-matrix adhesion between primary breast cancer cells derived
from node-positive and node-negative women to each of
fibronectin, vitronectin, laminin and type IV collagen was
analysed using the Mann-Whitney U-test. Differences in response
of patient-derived cell-matrix adhesion to inhibitors of integrin
function for a given ligand were assessed as paired data by the
Wilcoxon signed rank test. Good cell adhesion was defined as
attachment of more than 50% of cells in triplicate studies, while
attachment of less than 50% was considered poor adhesion. In
order to facilitate statistical analysis by avoiding small data sets,
integrin expression was dichotomized into positive and negative
staining by combining the weak (+), moderate (++) and strong
(+++) categories of positive expression. Integrin expression and
function were compared using Fisher's exact test.
RESULTS
Variation in primary breast cancer cell-matrix adhesion
with nodal status
The patient sample and tumour characteristics of the women
studied are shown in Table 1. Owing to limitations on cell quantity
required by these experiments, the actual number of patients
studied for each matrix protein were: fibronectin n = 40 [19 lymph
node-negative (LN-) and 21 lymph node-positive (LN+)],
vitronectin n = 40 (20 LN-, 20 LN +), laminin n = 39 (20 LN-, 19
LN +) and type IV collagen n = 39 (19 LN-, 20 LN+).
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Figure 3 Differential inhibition of primary breast cancer cell-matrix adhesion by RGD (150 ,g ml-') with nodal status to (A) fibronectin, (B) vitronectin, (C)
laminin and (D) type IV collagen, each matrix protein at concentrations of 100 ±gg ml-1. See legend to Figure 1 for the convention applied to box and whisker
plots. RGD, arginine-glycine-aspartate; RGE, arginine-glycine-glutamic acid (control); P, P-values, paired Wilcoxon test
Variation in adhesion of primary breast cancer cells with nodal
status is shown in Figure 1. Adhesion of primary breast cancer
cells from node-positive women to each offibronectin, vitronectin,
laminin and type IV collagen was significantly less than that of
node-negative patients (P<O.OO1, Mann-Whitney U-test). Primary
breast cancer cells that were predisposed to metastasize were thus
less adherent to the extracellular matrix than primary breast cancer
cells from lymph node-negative patients. To show that poor adhe-
sion of primary breast cancer cells from lymph node-positive
patients was not caused by inadequate incubation, cells from six
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Figure 4 Inhibition of primary breast cancer cell adhesion by varying concentrations of integrin monoclonal antibodies to (A) fibronectin, (B) vitronectin,
(C) laminin and (D) type IV collagen, each matrix at concentrations of 100 gg ml-'. Integrin-positive breast cancer cells were applied to matrix protein-coated
wells in triplicate. The bars represent the standard error of the mean. (--.O--)PIE6; (-z!Y)CLB-701; (-c--)7F12; (-fJ-)PIB5; (-17-)MAb 13; (-0-)PIF6
node-positive women were incubated for 8 h at 100 gg ml', and
for 4 h at 1000 ,ug ml-' of each matrix protein with no demon-
strable increase in cell adhesion. The inhibitory tripeptide RGD
and specific integrin monoclonal antibodies were used to show
that this difference in cell-matrix adhesion between lymph node-
positive and node-negative women was integrin mediated.
Variation in RGD inhibition of breast cancer cell
adhesion with nodal status
Differences in the inhibitory effects of RGD on primary breast
cancer cell adhesion to fibronectin, vitronectin, laminin and type
IV collagen with nodal status were investigated at concentrations
of 100 gg ml' of each matrix protein. The dose-response of
increased inhibition of cell-matrix adhesion by greater doses of
RGD is shown in Figure 2, using primary breast cancer cells
obtained from six consecutive integrin-positive patients. The inac-
tive tripeptide RGE was used as a control. Maximal inhibition of
cell-matrix adhesion was achieved using 150 ,ug ml-' RGD. This
concentration of RGD was therefore used to evaluate differential
inhibition of primary breast cancer cell adhesion to each matrix
protein by RGD (Figure 3). Cell-matrix adhesion of primary
breast cancer cells derived from lymph node-negative patients to
fibronectin, vitronectin and laminin were significantly inhibitedby
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Figure 5 Differences in inhibition of primary breast cancer cell-matrix adhesion with nodal status by integrin antibodies at concentrations of 75 ig ml to
(A) fibronectin, (B) vitronectin, (C) laminin and (D) collagen IV. Each matrix protein was coated at 100 ig in-'. See legend to Figure 1 for the convention applied
to the box and whisker plots. P, P-values, paired Wilcoxon test
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Table 2 Comparison of integrin expression and adhesive function to each matrix protein
Cell-matrix adhesion (expressed as % of total number of plated cells)
Fibronectin Vitronectin Laminin Type IV collagen
>50% <50% P >50% <50% p >50% <50% P >50% <50% p
Integrin expression
a2
+++ NA NA 1 0 1 0
++ 9 2 8 3
+ 5 1 4 1
0 3 16 < 0.001 3 16 < 0.001
Missing data 2 0 3 0
a3
0 0 NA 0 0 0 0
++ 4 2 6 1 4 2
+ 7 2 7 2 7 1
0 8 17 0.011 6 16 0.001 5 17 0.001
Missing data 0 0 1 0 3 0
a6
+++ NA NA 2 0 NA
++ 7 2
+ 6 2
0 4 15 <0.001
Missing data 1 0
1p
3 0 3 0 3 0 3 0
++ 6 4 7 5 12 1 7 4
+ 6 2 6 2 2 3 4 2
0 4 15 0.002 3 13 0.002 2 14 <0.001 3 14 0.002
Missing data 0 0 1 0 1 1 2 0
135
0 0 0 0 N/A NA
++ 0 1 0 1
+ 11 3 10 2
0 7 15 0.013 6 17 0.004
Missing data 1 2 4 1
Integrin expression was scored as strong (+++), moderate (++), weak (+), or negative staining (0) by two independent observers with consensus. Integrin
function was expressed as the mean percentage of cell adhesion plated in triplicate wells. Strong and weak adhesion was considered to be greater or less than
50% cell-matrix adhesion respectively. Missing data arising from insufficient numbers of cells for an experimental set is shown wherever appropriate. Integrin
subunits that were not applicable (NA) for a given matrix protein were not included. For non-parametric analysis, data for integrin expression were categorized
into positive and negative by combining the strong, moderate and weak staining groups. P-values were derived using Fisher's exact test.
RGD, but adhesion to type IV collagen was unaffected by this
tripeptide motif. Primary breast cancer cell adhesion to type IV
collagen may, therefore, be mediated through alternative peptide
recognition sequences. The control tripeptide RGE had no effect
on breast cancer cell adhesion to the extracellular matrix. Primary
breast cancer cells derived from lymph node-positive patients
were unaffected by RGD, although any effect on cell-matrix adhe-
sion may have been masked by weak adhesion even in the absence
ofinhibitory peptides.
Inhibition of primary breast cancer cell adhesion by
integrin antibodies
Relevant antibodies to the integrins were tested against each of
fibronectin, vitronectin, laminin and type IV collagen in primary
breast cancer cells obtained from six consecutive integrin-positive
tumours (Figure 4). Inhibition of cell-matrix adhesion by appro-
priate integrin monoclonal antibodies was achieved in adose-depen-
dent manner. Maximal inhibition of attachment was achieved at
concentrations of 75 gg ml-' of each integrin monoclonal antibody
for all the matrix proteins studied. PIF6, an inhibitory antibody
against avP5, had no effect on primary breast cancer cell adhesion
to fibronectin, even at a concentration of 150 gg ml-'. This suggests
that avP5 expressed in human breast cancer cells is not a receptor
for fibronectin. Each monoclonal antibody was used at concentra-
tions of75 pg ml-' to assess variation in the inhibition ofcell-matrix
adhesion with nodal status at 100 gg ml-' of each matrix protein
(Figure 5 A-D). Primary breast cancer cells derived from lymph
node-negative women demonstrated good adhesion to the extracel-
lular matrix and were inhibited by appropriate integrin monoclonal
antibodies. Cell adhesion to fibronectin was inhibited by antibodies
to the a3 and PI subunits; vitronectin by 1 andP5; laminin by a2.
a3, a6 and f 1; and type IV collagen by a2, a3 and [ 1.
Primary breast cancer cells derived from lymph node-positive
patients were poorly adherent to control wells that were incubated
in the absence of inhibitory monoclonal antibodies. This intrinsic
weak cell adhesion profile may conceal any potential effect of
integrin monoclonal antibodies on cell-matrix interaction.
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Integrin expression and function in primary breast
cancer cells
To compare integrin expression and function, the following inte-
grin subunits were used: c3, Pl and 05 for fibronectin; 01 and05
for vitronectin; cx2, c3, c6 and 01 for laminin; and cx2, cx3 and P1
for collagen type IV. A significant relationship between integrin
expression and cell-matrix adhesive function was demonstrated
using Fisher's exact test (Table 2). A proportion oftumours was not
assessed for both integrin expression and function for each subunit
because of insufficient numbers ofprimary breast cancer cells after
immunomagnetic separation. Missing variables were few and these
are listed for each matrix protein in Table 2. Positive integrin
expression in primary breast cancer cells assessed using immuno-
histochemistry was associated with good adhesion (> 50%) to
each of the matrix proteins studied, while the converse was true
for breast cancer cells with negative integrin expression. The
few patients that demonstrated strong integrin expression (+++)
all displayed strong adhesion in excess of 70%. This study
demonstrates for the first time a relationship between integrin
receptor expression and function in patient-derived human breast
cancer cells.
DISCUSSION
Interaction between cancer cells and the extracellular matrix is
known to influence tumour outcome (Ruoslahti, 1992) and may
provide a mechanism by which certain tumour types are prone to
metastasize. The cell adhesion molecules could be responsible for
this phenomenon with variable expression and function of these
receptors. Cell adhesion receptor function might be required for
cancer cell interaction with the endothelium of lymphovascular
channels and migration through the extracellular matrix at primary
as well as secondary sites (Aznavoorian et al, 1990). On the other
hand, down-regulation of cell adhesion molecule function might
be expected in order for cancer cells to detach from the primary
mass in the metastatic process. High integrin function is a recog-
nized stop signal in the control of cell migration in embryogenesis
(Duband et al, 1986). In cancer, reduced adhesion may result in
less sticky tumour cells able to move unhindered in the extracel-
lular matrix, thus predisposed to metastasize. Experimental work
on the tumour biology of metastasis has conventionally used cell
lines in in vitro and animal models. The relationship between these
models and the human situation is unreliable and attempts to
extrapolate the data from such experiments to the clinical context
is difficult. We, therefore, addressed this problem by the develop-
ment of a method of isolating human primary breast cancer cells
for use in short-term in vitro studies.
The role of the integrins in modulating matrix adhesion in
primary breast cancer cells from individual patients with known
tumour characteristics has not been investigated previously. We
and others have identified specific integrin subunits that are down-
regulated in breast cancer (Zutter et al, 1990; Pignatelli et al, 1991;
Koukoulis et al, 1991; Gui et al, 1995a), leading to the use of
specific monoclonal antibodies to study function. Our results indi-
cate that primary breast cancer cells from node-negative women
were significantly more adherent to each of fibronectin, vitro-
nectin, laminin and type IV collagen compared with primary
breast cancer cells derived from node-positive patients (Figure 1).
This was shown to be mediated, at least in part, by integrin inter-
action using the inhibitory tripeptide RGD (Figure 3). Inhibition of
cell adhesionby RGD reflects therecognitionby integrin receptors
ofthis motif in the extracellular matrix. In node-negative women,
breast cancer cell adhesion to fibronectin, vitronectin and laminin
was significantly inhibited by RGD. The apparent inactivity of
RGD in mediating cell binding to collagen IV probably results
from the relative unimportance of this motif as a recognition
sequence in cell-matrix adhesion to this ligand. RGD has been
shown to have an important role in the modulation ofother home-
ostatic cellularmechanisms, such as the regulation ofcytoplasmic
calcium levels inpancreatic acini bycollagen type IV (Somogyi et
al, 1994). We were unable to demonstrate any RGD-mediated
effect on cell adhesion to type IV collagen in this study.
The specific influence ofeach integrin receptor was then further
assessed using monoclonal antibodies directed against individual
subunits. Primary breast cancer cell-matrix adhesion of node-
negative women was significantly reduced compared with control
wells using the paired Wilcoxon test (Figure 5). Inhibition of
breast cancer cell adhesion by monoclonal antibodies in node-
negative women was consistent with previous knowledge of inte-
grin receptor-ligand interactions (Hynes, 1992). Thus, cell
adhesion to fibronectin was inhibited by antibodies to the 031l
integrin; vitronectin by av,l and cxvp5; laminin by a2pl, a3pl
and a6pl; and type IV collagen by a2pl and a3pl. There were
two interesting exceptions: P1F6 (anti-P5) did not inhibit cell
adhesion to fibronectin and 7F12 (anti-,3) failed to inhibit attach-
ment to vitronectin (Figure 5A andB). Fromthis, we can conclude
that, in human primary breast cancer, av15 is a vitronectin but not
a fibronectin receptor, although it has been shown to recognize
both proteins in other cell types (Albelda and Buck, 1990). The
avP3 integrin did not influence cell adhesion in breast cancer cells
and this supports ourprevious finding that alteredexpression of ,3
is not a determinant ofnodal status (Gui et al, 1995a).
Cell-matrix adhesion ofprimary breast cancers fromnode-posi-
tive women demonstrated poor adhesion and was not affected by
inhibitory peptides or antibodies, providing functional evidence
that these cells had lost integrin expression. The differences in
integrin-mediatedprimary breast cancer cell-matrix adhesion with
nodal status were shown to be unrelated to extreme incubation
times, matrix protein and inhibitor concentrations. These data
support the hypothesis that primary breast cancer cells that have
lost integrin function are predisposed to metastasize.
Immunochemistry may be criticized as a method of investi-
gating the multistep process of tumour metastasis, as it provides
only a snapshot of a dynamic process. Expression of cell surface
receptors demonstrated by special stains may not relate to func-
tional activity. In this study, we have shown a significant relation-
ship between integrin expression and adhesive function (Table 2).
However, aproportion ofprimary breast cancercells with weak(+)
or moderate (++) integrin expression demonstrated poor adhesion
to the extracellular matrix, suggesting some receptors are only
partially functional or non-functional. The discrepancy between
integrin expression and function observed in a proportion of cases
may also have arisen because of the complex relationship between
the integrins and their ligands. As an example, consider the a201
and x301 integrins that are receptors to both laminin (Languino et
al, 1989) and collagen (Santoro et al, 1988). Positive integrin
expression ofcx2pl and O3p1 measured using immunochemistry
might have been interpreted erroneously as an indicator of a func-
tional relationship with either protein. Another reason for this
observation may be the non-availability of functional monoclonal
antibodies against the Il, av, -6 and
- 8 subunits. The xv subunit
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forms distinct integrin heterodimers with both these newly discov-
eredP6 andP8 subunits, as well asP1, ,B3 andP5.Therole ofav,6
and avP8 integrins in breast cancer progression therefore remains
to be clarified. The mechanism by which integrin receptors are able
to recognize multiple ligands is as yet uncertain. Integrin receptor
heterodimers that bind to identical proteins are known to recognize
specific epitopes that are spatially distinct on the matrix macromol-
ecule (Humphries et al, 1987; Hall et al, 1990).
Integrin receptors undergo conformational change between an
active and inactive state (Hynes, 1992), and receptor activation
may be influenced by a variety of factors. Modulation of integrin
receptor function might be regulated by direct ligation of the
receptor itself (outside-in signalling), a phenomenon associated
with receptor clustering (Philips et al, 1988). However, integrin
expression is mainly thought to be regulated by inside-out
signalling through a variety oftissue and soluble factors, including
the cell adhesion molecule CD44 (Koopman et al, 1990), c-erbB-2
(D'Souza et al, 1993), and the interleukins IL-12 (Rabinowich et
al, 1993a) and IL-6 (Rabinowich et al, 1993b). Integrin expression
is also dependent on the divalent cations calcium and manganese
(Humphries, 1990). The regulation ofintegrin receptor expression
and function in tumour progression is currently being investigated
in our laboratory.
The cellular effects modulated by integrin expression in tumour
invasion may only be empirically related to cell-matrix adhesion.
Loss of integrin expression may predispose to tumour progression
by the loss ofregulatory control overgrowth and differentiation. In
in vitro studies,transfection ofChinese hamster ovary cells with the
cDNA for the a5PI fibronectin receptor inhibits the ability ofthese
cells to grow and establish tumours in nude mice (Giancotti and
Ruoslahti, 1990). Cancer cells with decreased integrin expression
may thus display greater invasive potential (Schreiner et al, 1991).
The biology of tumour metastasis is still not well understood.
We have shown that loss of integrin expression and function in
primary breast cancer cells are related to reduced matrix adhesion
in the presence ofaxillary nodal metastasis. Altered integrin-medi-
ated adhesion ofcancer cells to the extracellular matrix is a critical
factor in the metastatic cascade. The integrins may, thus, be of
clinical value as predictors of nodal status in patients with breast
cancer at the time of symptomatic presentation. The prognostic
significance of integrin expression in determining disease-free
interval and overall survival in breast cancer progression remains
to be defined.
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